Blood: The Otub1/c-Maf axis may be a potential therapeutic target for multiple myeloma.

Cancer-causing transcription factor c-Maf has been considered an ideal therapeutic target for multiple myeloma (MM), but how this can be achieved remains unclear.
the study, the researchers found that the Otub1/c-Maf axis could be a potential target.
Otub1, which belongs to the OTU family of de-ubibinases, has been found to interact with c-Maf.
Otub1 can abolish polypronination of c-Maf K48 connections, preventing degradation and enhancing their transcriptional activity.
specifically, this de-ubitinization activity depends on its Lys71 and N ends, but not on UCE2O, a known c-Maf E2.
Otub1 promotes MM cell survival and MM tumor growth.
, silence Otub1 can lead to c-Maf degradation and c-Maf expressive MM apoptosis.
, the Otub1/c-Maf axis may be a therapeutic target for MM.
To explore this hypothesization, the researchers screened FDA-approved drugs and natural products using c-Maf-identified original fluorin-driven reporting trials and found that the original strong glycoside, anthromosine C (LanC), prevented C-Maf de-ubibination and induced its degradation by interfering with the interactions between Otub1 and C-Maf.
further experiments have shown that LanC inhibits c-Maf transcription activity, induces c-Maf expressive MM apoptosis, inhibits MM growth, and prolongs the overall survival of mouse models without significant toxicity.
, the study suggests that Otub1 is a new de-ubibinase for c-Maf, suggesting that Otub1/c-Maf may be a potential therapeutic target for MM.
.